523 results
Keyword EPAR Remove keyword
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Taltz (updated)
ixekizumab, Psoriasis
Date of authorisation: 25/04/2016,
, Revision: 11, Authorised, Last updated: 04/01/2021
information. Abbreviated as EPAR. More information can be found … public assessment report (EPAR) for Taltz. It explains how … characteristics (also part of the EPAR). How does Taltz work? The … -
List item
Human medicine European public assessment report (EPAR): Ozempic (updated)
semaglutide, Diabetes Mellitus
Date of authorisation: 08/02/2018,, Revision: 4, Authorised, Last updated: 11/01/2021
information. Abbreviated as EPAR. More information can be found … public assessment report (EPAR) for Ozempic. It explains … 8 February 2018. The full EPAR for Ozempic can be found … -
List item
Human medicine European public assessment report (EPAR): Ocrevus (updated)
ocrelizumab, Multiple Sclerosis
Date of authorisation: 08/01/2018,, Revision: 8, Authorised, Last updated: 11/01/2021
information. Abbreviated as EPAR. More information can be found … public assessment report (EPAR) for Ocrevus. It explains … leaflet (also part of the EPAR) or contact your doctor or … -
List item
Human medicine European public assessment report (EPAR): Keytruda (updated)
Pembrolizumab, Melanoma, Hodgkin Disease, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urologic Neoplasms, Squamous Cell Carcinoma of Head and Neck
Date of authorisation: 17/07/2015,, Revision: 30, Authorised, Last updated: 21/12/2020
Summary documents Keytruda : EPAR - Medicine overview PDF icon … -
List item
Human medicine European public assessment report (EPAR): Axumin (updated)
Fluciclovine (18F), Prostatic Neoplasms, Radionuclide Imaging
Date of authorisation: 21/05/2017,, Revision: 10, Authorised, Last updated: 11/01/2021
information. Abbreviated as EPAR. More information can be found … public assessment report (EPAR) for Axumin. It explains … leaflet (also part of the EPAR) or contact your doctor or … -
List item
Human medicine European public assessment report (EPAR): Kisplyx (updated)
lenvatinib mesilate, Carcinoma, Renal Cell
Date of authorisation: 25/08/2016,, 
, Revision: 12, Authorised, Last updated: 14/01/2021
information. Abbreviated as EPAR. More information can be found … public assessment report (EPAR) for Kisplyx. It explains … leaflet (also part of the EPAR) or contact your doctor or … -
List item
Human medicine European public assessment report (EPAR): Gilenya (updated)
fingolimod hydrochloride , Multiple Sclerosis
Date of authorisation: 17/03/2011,
, , Revision: 27, Authorised, Last updated: 18/12/2020
Gilenya : EPAR - Medicine overview (PDF/81.82 … -
List item
Human medicine European public assessment report (EPAR): Alofisel (updated)
darvadstrocel, Rectal Fistula
Date of authorisation: 23/03/2018,, 
, Revision: 6, Authorised, Last updated: 04/01/2021
information. Abbreviated as EPAR. More information can be found … public assessment report (EPAR) for Alofisel. It explains … leaflet (also part of the EPAR) or contact your doctor or … -
List item
Human medicine European public assessment report (EPAR): Zepatier
elbasvir, grazoprevir, Hepatitis C, Chronic
Date of authorisation: 22/07/2016,, Revision: 10, Authorised, Last updated: 08/12/2020
information. Abbreviated as EPAR. More information can be found … public assessment report (EPAR) for Zepatier. It explains … characteristics (also part of the EPAR). How does Zepatier work? The … -
List item
Human medicine European public assessment report (EPAR): Revlimid
lenalidomide, Multiple Myeloma, Lymphoma, Mantle-Cell, Myelodysplastic Syndromes
Date of authorisation: 14/06/2007,, Revision: 43, Authorised, Last updated: 17/12/2020
Summary documents Revlimid : EPAR - Medicine overview PDF icon … -
List item
Human medicine European public assessment report (EPAR): Alprolix
eftrenonacog alfa, Hemophilia B
Date of authorisation: 12/05/2016,, , Revision: 5, Authorised, Last updated: 04/11/2020
public assessment report (EPAR) for Alprolix. It explains … characteristics (also part of the EPAR). Patients or their carers … leaflet (also part of the EPAR) or contact your doctor or … -
List item
Human medicine European public assessment report (EPAR): Alpivab
Peramivir, Influenza, Human
Date of authorisation: 13/04/2018,, Revision: 2, Withdrawn, Last updated: 09/12/2020
Summary documents Alpivab : EPAR - Medicine overview PDF icon … product characteristics This EPAR was last updated on 09/12/2020 … EMEA/H/C/004299 - T/0004 Alpivab : EPAR - Product Information PDF … -
List item
Human medicine European public assessment report (EPAR): Holoclar (updated)
ex vivo expanded autologous human corneal epithelial cells containing stem cells, Stem Cell Transplantation, Corneal Diseases
Date of authorisation: 17/02/2015,, , 
, Revision: 7, Authorised, Last updated: 14/01/2021
information. Abbreviated as EPAR. More information can be found … public assessment report (EPAR) for Holoclar. It explains … characteristics (also part of the EPAR). How does Holoclar work? The … -
List item
Human medicine European public assessment report (EPAR): Tysabri
natalizumab, Multiple Sclerosis
Date of authorisation: 27/06/2006,, Revision: 32, Authorised, Last updated: 11/12/2020
Summary documents Tysabri : EPAR - Medicine overview PDF icon … -
List item
Human medicine European public assessment report (EPAR): Veklury (updated)
remdesivir, Coronavirus Infections
Date of authorisation: 03/07/2020,, , Revision: 4, Authorised, Last updated: 22/12/2020
Summary documents Veklury : EPAR - Medicine overview PDF icon … EMA/676677/2020 Generic Veklury : EPAR – Risk management plan … product characteristics This EPAR was last updated on 22/12/2020 … -
List item
Human medicine European public assessment report (EPAR): Anoro Ellipta (previously Anoro) (updated)
umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 08/05/2014,, Revision: 15, Authorised, Last updated: 22/12/2020
documents Anoro Ellipta : EPAR - Medicine overview PDF icon … -
List item
Human medicine European public assessment report (EPAR): Epclusa
Sofosbuvir, velpatasvir, Hepatitis C, Chronic
Date of authorisation: 06/07/2016,, , Revision: 13, Authorised, Last updated: 11/12/2020
Summary documents Epclusa : EPAR - Medicine overview PDF icon … EMA/661130/2020 Generic Epclusa : EPAR - Risk-management-plan summary … product characteristics This EPAR was last updated on 11/12/2020 … -
List item
Human medicine European public assessment report (EPAR): Neparvis
sacubitril, valsartan, Heart Failure
Date of authorisation: 26/05/2016,, Revision: 10, Authorised, Last updated: 07/12/2020
information. Abbreviated as EPAR. More information can be found … public assessment report (EPAR) for Neparvis. It explains … characteristics (also part of the EPAR). How does Neparvis work? The … -
List item
Human medicine European public assessment report (EPAR): Caprelsa
Vandetanib, Thyroid Neoplasms
Date of authorisation: 16/02/2012,, , Revision: 18, Authorised, Last updated: 07/12/2020
information. Abbreviated as EPAR. More information can be found … public assessment report (EPAR) for Caprelsa. It explains … EMA/797340/2016 EMEA/H/C/002315 EPAR summary for the public Caprelsa … -
List item
Human medicine European public assessment report (EPAR): Ninlaro (updated)
ixazomib citrate, Multiple Myeloma
Date of authorisation: 21/11/2016,, , , Revision: 8, Authorised, Last updated: 08/01/2021
information. Abbreviated as EPAR. More information can be found … public assessment report (EPAR) for Ninlaro. It explains … leaflet (also part of the EPAR) or contact your doctor or … -
List item
Human medicine European public assessment report (EPAR): Imnovid (previously Pomalidomide Celgene) (updated)
Pomalidomide, Multiple Myeloma
Date of authorisation: 05/08/2013,, , Revision: 17, Authorised, Last updated: 18/12/2020
Imnovid : EPAR - Medicine overview (PDF/75.85 … -
List item
Human medicine European public assessment report (EPAR): Ontruzant (updated)
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 15/11/2017,, 
, Revision: 7, Authorised, Last updated: 04/01/2021
information. Abbreviated as EPAR. More information can be found … public assessment report (EPAR) for Ontruzant. It explains … leaflet (also part of the EPAR) or contact your doctor or … -
List item
Human medicine European public assessment report (EPAR): Quinsair
levofloxacin, Cystic Fibrosis, Respiratory Tract Infections
Date of authorisation: 25/03/2015,, Revision: 12, Authorised, Last updated: 15/12/2020
information. Abbreviated as EPAR. More information can be found … public assessment report (EPAR) for Quinsair. It explains … EMA/1805/2015 EMEA/H/C/002789 EPAR summary for the public Quinsair … -
List item
Human medicine European public assessment report (EPAR): Mysimba
bupropion hydrochloride, naltrexone hydrochloride, Obesity, Overweight
Date of authorisation: 26/03/2015,, Revision: 18, Authorised, Last updated: 14/12/2020
information. Abbreviated as EPAR. More information can be found … public assessment report (EPAR) for Mysimba. It explains … EMA/83596/2015 EMEA/H/C/003687 EPAR summary for the public Mysimba … -
List item
Human medicine European public assessment report (EPAR): Orkambi
Lumacaftor, ivacaftor, Cystic Fibrosis
Date of authorisation: 18/11/2015,, Revision: 24, Authorised, Last updated: 14/12/2020
Summary documents Orkambi : EPAR - Medicine overview PDF icon … 29/01/2019 Generic Orkambi : EPAR - Risk-management-plan summary … product characteristics This EPAR was last updated on 14/12/2020 …